Pfizer

Please use landscape view or desktop screen to view the content.

Body Weight–Related Definitions

BMI values for healthy weight, overweight, and obesity1,2

Corresponding weight in pounds (approximate)
Weight BMI values (kg/m2) Man 5’9” tall (average height) Woman 5’4” tall (average height)
Healthy weight 18.5–24.9 121–163 108–144
Overweight 25.0–29.9 164–195 145–173
Obese ≥30 ≥196 ≥174
Extreme/severe/morbidly obese ≥40 ≥271 ≥232

US average adult body weight

Male: 88.8 kg (195.8 lbs)

Female: 76.4 kg (168.4 lbs)3

Obesity is frequently subdivided into BMI (kg/m2)* categories4:

  • Class 1: BMI of 30 to <35
  • Class 2: BMI of 35 to <40
  • Class 3: BMI of 40 or higher (also categorized as “extreme” or “severe” obesity)

*BMI is calculated as: weight/height (kg/m2).
BMI, body mass index; US, United States.

*BMI is calculated as: weight/height (kg/m2).
BMI, body mass index; US, United States.

Reference
Menu Icon
Home Icon
  • Executive Summary Executive Summary Executive Summary
  • Body Weight–Related Definitions Body Weight–Related Definitions Body Weight–Related
    Definitions
  • Effects of Body Weight on Pharmacokinetics Effects of Body Weight on Pharmacokinetics Effects of Body Weight on Pharmacokinetics Menu Arrow Menu Arrow
    • Healthy Volunteers Menu Arrow Menu Arrow
      • Study design
      • Pharmacokinetics
      • Apixaban conc. vs. time
        and vs. antiXa activity
    • NVAF
    • VTE
  • US Label – Apixaban Effects on Body Weight US Label – Apixaban Effects on Body Weight US Label – Apixaban Effects on Body Weight Menu Arrow Menu Arrow
    • Dosing Recommendations
  • Treatment Guideline Recommendations Treatment Guideline Recommendations Guidance Recommendations Menu Arrow Menu Arrow
    • 2021 ISTH SCC Guidance
    • Expert Consensus Panel
  • Baseline Weight in Pivotal studies Baseline Weight in Pivotal studies Baseline Weight
    in Pivotal studies
  • Studies by Indication Studies by Indication Studies by Indication Menu Arrow Menu Arrow
    • NVAF Menu Arrow Menu Arrow
      • NVAF study overview
      • Apixaban Randomized Controlled Clinical Trial Data
      • ARISTOTLE Weight Subgroup Analysis (post hoc) Hohnloser et al.
      • ARISTOTLE BMI Analysis (post hoc) Sandhu et al.
      • Real-World Data
      • ARISTOPHANES 2020 Menu Arrow Menu Arrow
        • Objective
        • Study design
        • Results
      • Deitelzweig VA and Medicare 2022
      • Briasoulis 2021
      • O'Kane 2022
      • Kushnir 2019
    • VTE Menu Arrow Menu Arrow
      • VTE study overview
      • Apixaban Randomized Clinical Trial Data
      • AMPLIFY
      • AMPLIFY Post hoc Analysis
      • AMP-EXT
      • Real-World Data
      • Cohen 2021 (BMI ≥ 30 kg/m2)
      • Perino 2021 (BMI ≥ 40 kg/m2 or ≥ 120 kg)
      • Crouch 2022 (BMI ≥ 40 kg/m2 or ≥ 120 kg)
      • Kushnir 2019 (BMI ≥ 40 kg/m2)
    • Hip/Knee Replacement Menu Arrow Menu Arrow
      • ADVANCE-1
      • ADVANCE-2
      • ADVANCE-3
      • ADVANCE-2 and ADVANCE-3 weight and BMI Subgroup Analysis.
  • Appendix Appendix Appendix Menu Arrow Menu Arrow
    • Limitations/Disclaimers
Pfizer
Tooltip Close

References

  1. National and Health and Nutrition Examination Survey. CDC. Accessed August 01, 2022. https://www.cdc.gov/nchs/data/nhanes/databriefs/adultweight.pdf
  2. National Heart, Lung, and Blood Institute. NIH. Accessed December 27, 2022. https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi_tbl2.htm
  3. Fryar CD, Gu Q, Ogden CL, Flegal KM. Anthropometric reference data for children and adults: United States, 2011-2014. National Center for Health Statistics. Vital Health Stat 3. 2016;39:1-46.
  4. Overweight and obesity. Centers for Disease Control and Prevention. Accessed August 01, 2022. https://www.cdc.gov/obesity/adult/defining.html